AR060186A1 - Inhibidores de la prenil-transferasa para el control de la hipertension ocular y el tratamiento del glaucoma - Google Patents

Inhibidores de la prenil-transferasa para el control de la hipertension ocular y el tratamiento del glaucoma

Info

Publication number
AR060186A1
AR060186A1 ARP070101305A ARP070101305A AR060186A1 AR 060186 A1 AR060186 A1 AR 060186A1 AR P070101305 A ARP070101305 A AR P070101305A AR P070101305 A ARP070101305 A AR P070101305A AR 060186 A1 AR060186 A1 AR 060186A1
Authority
AR
Argentina
Prior art keywords
ggti
glaucoma
treatment
fti
prenil
Prior art date
Application number
ARP070101305A
Other languages
English (en)
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Publication of AR060186A1 publication Critical patent/AR060186A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un método para tratar el glaucoma o presion intraocular elevada que comprende administrar una cantidad eficaz farmacéutica de una composicion que comprende por lo menos un inhibidor de prenil-transferasa. Una composicion para el tratamiento de la presion intraocular elevada y del glaucoma que comprende una cantidad eficaz farmacéutica de un inhibidor de prenil-transferasa. Reivindicacion 14: La composicion de acuerdo con la reivindicacion 8 donde dicho inhibidor de preniltransferasa se selecciona del grupo formado por: GGTI-286, GGTI-287, GGTI-297, GGTI-298, GGTI-2133, GGTI-2147, FTI-276, FTI-277, FTI-2148, FTI-2153, R115777, sus combinaciones y sus sales aceptables para uso farmacéutico.
ARP070101305A 2006-03-31 2007-03-28 Inhibidores de la prenil-transferasa para el control de la hipertension ocular y el tratamiento del glaucoma AR060186A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78797106P 2006-03-31 2006-03-31

Publications (1)

Publication Number Publication Date
AR060186A1 true AR060186A1 (es) 2008-05-28

Family

ID=38230203

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101305A AR060186A1 (es) 2006-03-31 2007-03-28 Inhibidores de la prenil-transferasa para el control de la hipertension ocular y el tratamiento del glaucoma

Country Status (14)

Country Link
US (3) US20070232675A1 (es)
EP (1) EP2001457A1 (es)
JP (1) JP2009532377A (es)
KR (1) KR20080111092A (es)
CN (1) CN101410104A (es)
AR (1) AR060186A1 (es)
AU (1) AU2007234903B2 (es)
BR (1) BRPI0710122A2 (es)
CA (1) CA2645171A1 (es)
MX (1) MX2008012662A (es)
RU (1) RU2008143219A (es)
TW (1) TW200806284A (es)
WO (1) WO2007118009A1 (es)
ZA (1) ZA200807828B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786463B2 (en) 2017-08-27 2023-10-17 Rhodes Technologies Pharmaceutical compositions for the treatment of ophthalmic conditions
US20210008084A1 (en) 2017-10-16 2021-01-14 Tsinghua University Mevalonate pathway inhibitor and pharmaceutical composition thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US6627610B1 (en) * 1992-05-29 2003-09-30 Jeffrey Glenn Method for inhibition of viral morphogenesis
US5578477A (en) * 1993-01-05 1996-11-26 Arch Development Corporation Identification and characterization of inhibtors of protein farnesyltransferase
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6011175A (en) * 1993-05-18 2000-01-04 University Of Pittsburgh Inhibition of farnesyltransferase
US5965539A (en) * 1993-05-18 1999-10-12 Univeristy Of Pittsburgh Inhibitors of prenyl transferases
US5602098A (en) * 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
US5705686A (en) * 1993-05-18 1998-01-06 University Of Pittsburgh Inhibition of farnesyl transferase
US5834434A (en) * 1993-05-18 1998-11-10 University Of Pittsburgh Inhibitors of farnesyltransferase
US5458883A (en) * 1994-01-12 1995-10-17 Duke University Method of treating disorders of the eye
US5789558A (en) * 1994-01-31 1998-08-04 Merck & Co., Inc. Protein prenyltransferase
US5631401A (en) * 1994-02-09 1997-05-20 Abbott Laboratories Inhibitors of protein farnesyltransferase and squalene synthase
US5430055A (en) * 1994-04-08 1995-07-04 Pfizer Inc. Inhibitor of squalene synthase
ATE183502T1 (de) * 1994-04-15 1999-09-15 Takeda Chemical Industries Ltd Octahydro-2-naphthalincarbonsäure-derivate, ihre herstellung und verwendung
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
US5585359A (en) * 1994-09-29 1996-12-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5571835A (en) * 1994-09-29 1996-11-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5831115A (en) * 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
EP0856315B1 (en) * 1995-08-09 2005-08-24 Banyu Pharmaceutical Co., Ltd. Protein-farnesyltransferase inhibitors in combination with hmgcoa-reductase-inhibitors for the treatment of aids
US6693123B2 (en) * 1995-11-06 2004-02-17 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6204293B1 (en) * 1995-11-06 2001-03-20 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6310095B1 (en) * 1995-11-06 2001-10-30 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
AU7985698A (en) * 1997-06-19 1999-01-04 Johns Hopkins University, The Methods for treatment of ocular neovascularization
US7262338B2 (en) * 1998-11-13 2007-08-28 Performance Plants, Inc. Stress tolerance and delayed senescence in plants
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
NZ511995A (en) * 1999-01-21 2003-11-28 Bristol Myers Squibb Co A ras-farnesyltransferase inhibitor complex that is stable and water soluble and useful as an anti-tumour agent
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6436972B1 (en) * 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
US20020019527A1 (en) * 2000-04-27 2002-02-14 Wei-Bo Wang Substituted phenyl farnesyltransferase inhibitors
WO2001081316A2 (en) * 2000-04-27 2001-11-01 Abbott Laboratories Substituted phenyl farnesyltransferase inhibitors
EP1283728A2 (en) * 2000-05-23 2003-02-19 Amersham Health AS Contrast agents
CA2414403A1 (en) * 2000-07-06 2002-01-17 The Regents Of The University Of California Methods for diagnosis and treatment of psychiatric disorders
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
US7211595B2 (en) * 2000-11-30 2007-05-01 Abbott Laboratories Farnesyltransferase inhibitors
US7238514B2 (en) * 2001-01-05 2007-07-03 William Marsh Rice University Diterpene-producing unicellular organism
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
AU2002310441A1 (en) * 2001-06-14 2003-01-02 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
KR20050044570A (ko) * 2001-11-23 2005-05-12 추가이 세이야쿠 가부시키가이샤 종양 표적 효소의 동정 방법
US20030199542A1 (en) * 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
US20030199544A1 (en) * 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
US20030216441A1 (en) * 2002-05-10 2003-11-20 Gwaltney Stephen L. Farnesyltransferase inhibitors
US20060276486A1 (en) * 2003-04-17 2006-12-07 Kowa Co., Ktd. Lklf/klf2 gene expression promoter
JP2005073550A (ja) * 2003-08-29 2005-03-24 Toyota Motor Corp プレニルアルコールの製造方法
JP4691041B2 (ja) * 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
WO2006116716A2 (en) * 2005-04-27 2006-11-02 University Of Florida Materials and methods for enhanced degradation of mutant proteins associated with human disease

Also Published As

Publication number Publication date
US20070232675A1 (en) 2007-10-04
MX2008012662A (es) 2008-10-13
AU2007234903B2 (en) 2012-03-01
CN101410104A (zh) 2009-04-15
AU2007234903A1 (en) 2007-10-18
EP2001457A1 (en) 2008-12-17
US20100120851A1 (en) 2010-05-13
ZA200807828B (en) 2009-11-25
CA2645171A1 (en) 2007-10-18
TW200806284A (en) 2008-02-01
JP2009532377A (ja) 2009-09-10
BRPI0710122A2 (pt) 2011-08-02
KR20080111092A (ko) 2008-12-22
WO2007118009A1 (en) 2007-10-18
US20120108632A1 (en) 2012-05-03
RU2008143219A (ru) 2010-05-10

Similar Documents

Publication Publication Date Title
CL2020003330A1 (es) Moléculas de ácido nucleico para la reducción de arnm de papd5 o papd7 para tratar la infección por hepatitis b (divisional solicitud no. 3561-2018)
AR116753A1 (es) Proceso de preparación de un derivado de pirazolsulfonilamida
CL2008003405A1 (es) Compuestos derivados de tienopiridina, inhibidores de la enzima integrasa del vih; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion por vih.
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
SV2009003283A (es) Inhibidores de la actividad de la akt
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
UY30060A1 (es) Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
SV2009002861A (es) Compuestos de pirimidina amida como inhibidores de pgds
UY30511A1 (es) Agonistas de ep2
NI202100018A (es) Moduladores de la expresión de pnpla3
BR112012006010A2 (pt) composto de glicina
BR112017024245A2 (pt) ?método para tratamento de bexiga hiperativa, e, sistema para dispensação de vapor?.
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
CO6321186A2 (es) Metodo de control de malezas y composiciones herbicidas
ECSP22089507A (es) Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo
CL2022000214A1 (es) Inhibidores de enzimas
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
CL2007001826A1 (es) Compuestos derivados de 2-(amino-sustituido)-benzotiazol-sulfonamida, inhibidores de proteasa, en particular, inhibidores de proteasa de vih; composicion farmaceutica; y uso para tratar o combatir una infeccion o enfermedad asociada con la infeccion de un retrovirus resistente a multiples farmacos.
CL2022002699A1 (es) Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton.
CO2022000270A2 (es) Inhibidores de enzimas
UY39504A (es) Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
AR060186A1 (es) Inhibidores de la prenil-transferasa para el control de la hipertension ocular y el tratamiento del glaucoma
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan

Legal Events

Date Code Title Description
FA Abandonment or withdrawal